Burosumab
Burosumab-Twza is a monoclonal antibody medication designed to treat certain rare disorders affecting phosphate metabolism in the kidneys. It works by inhibiting a protein called fibroblast growth factor 23 (FGF23), which helps regulate phosphate levels in the body. This medication is primarily used in patients with specific genetic or tumor-related conditions that cause abnormally low phosphate levels in the blood.
Burosumab-Twza is an injectable monoclonal antibody used to treat rare disorders causing low blood phosphate levels by blocking FGF23 activity.
Key facts at a glance
- RxNorm
- 2043854
- Generic
- Burosumab-Twza
- Class
- pin-variant
- Brands
- Crysvita
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Burosumab-Twza is indicated for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), both conditions characterized by impaired phosphate reabsorption in the kidneys leading to chronic phosphate wasting and associated bone problems.
This medication is a monoclonal antibody that specifically binds to and neutralizes fibroblast growth factor 23 (FGF23), a hormone that normally reduces phosphate reabsorption in the kidneys. By blocking FGF23, burosumab-twza increases phosphate reabsorption and improves phosphate levels in the blood.
Burosumab-Twza is administered by subcutaneous injection and requires regular monitoring of serum phosphate levels. It should not be used in patients with severe kidney impairment or end-stage renal disease. Common side effects may include injection site reactions, headache, and tooth abscesses. This medication should only be prescribed by specialists familiar with the management of these rare mineral disorders.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy